Summary & Overview
HCPCS J7606: Formoterol Fumarate Inhalation Solution, DME Unit Dose 20 mcg
HCPCS Level II code J7606 designates formoterol fumarate inhalation solution — an FDA‑approved, non‑compounded unit‑dose bronchodilator formulated for administration through durable medical equipment (DME) in 20 microgram doses. This code identifies a specific inhalation therapy product used in outpatient and home-based respiratory management and matters nationally because it ties product-specific billing to the provision of DME-administered inhaled long-acting bronchodilator therapy.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, expected sites of service, and how payers typically classify DME-administered inhalation products. The publication summarizes reimbursement and coverage considerations at a national level, highlights common billing modifiers and administrative details provided in the input, and outlines where data is not available.
This report is intended to help billing staff, revenue cycle managers, and policy analysts understand the clinical identity of J7606, the service setting implications of DME‑delivered inhalation therapy, and the payer landscape relevant to claims processing and contract interpretation. Data not available in the input is noted where applicable.
Billing Code Overview
HCPCS Level II code J7606 represents formoterol fumarate inhalation solution, FDA-approved final product, non-compounded, administered through durable medical equipment (DME), unit dose form, 20 micrograms. The service type is inhalation bronchodilator therapy delivered via DME. The typical site of service is home or outpatient settings where DME is used to administer inhaled medications, including patient residences when DME is supplied or maintained by a provider.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 58-year-old patient with moderate persistent asthma and a history of exercise-induced bronchospasm presents for maintenance inhaled long-acting beta-agonist therapy. The patient receives a unit-dose, FDA-approved formoterol fumarate inhalation solution, 20 micrograms, supplied for administration through durable medical equipment (nebulizer) in a home or facility setting. The clinical workflow includes physician assessment and prescription of the inhalation solution, documentation of indication and dosage in the medical record, coordination with durable medical equipment suppliers for delivery, verification of patient ability to use nebulizer equipment, and periodic follow-up for symptom control and adverse effect monitoring. Billing uses the HCPCS Level II code J7606 for the drug supply; claims include relevant place-of-service, provider identifiers, and an appropriate modifier when applicable. Typical site of service is outpatient clinic, patient home (DME use), or skilled nursing facility where nebulized medication administration via DME is provided.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Returned to provider, no longer used | Rarely used; apply if medication is returned unused to pharmacy per payer rules |